206 related articles for article (PubMed ID: 2330805)
1. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
Lin SF; Liu HW; Chen TP
Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
[TBL] [Abstract][Full Text] [Related]
2. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
Insiripong S; Thaisamakr S
J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
[TBL] [Abstract][Full Text] [Related]
3. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
4. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
Jehn U; Göldel N; Vehling-Kaiser U
Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
[TBL] [Abstract][Full Text] [Related]
5. The results of treatment of selected patients with ANLL with low-dose Ara-C.
Pawelski S; Brodzki LM; Gepner-Woźniewska M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(1):71-4. PubMed ID: 2472330
[TBL] [Abstract][Full Text] [Related]
6. [An aged patient with acute myelogenous leukemia complicated with liver cirrhosis: successful treatment with low-dose cytosine arabinoside].
Saigo K; Ozaki S; Ueda K; Ryo R; Tatsumi E; Yamaguchi N
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2441-4. PubMed ID: 2751321
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences].
Fukushima T; Ueda T; Kamiya K; Yoshida W; Tsutani H; Uchida M; Nakamura T; Kagawa D; Domae N
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):126-31. PubMed ID: 2324584
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
Urabe A; Mizoguchi H; Hoshino S; Nomura T; Dan K; Toyama K; Kimura M; Ogawa T; Yamaguchi H; Mutoh Y
Int J Hematol; 1991 Feb; 54(1):75-7. PubMed ID: 1954354
[TBL] [Abstract][Full Text] [Related]
10. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
Chen YC; Lin SF; Yao M; Chen TY; Tsao CJ; Chen TP
Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
[TBL] [Abstract][Full Text] [Related]
12. [Low-dose cytosine arabinoside (ARA-C) in the treatment of acute myeloid leukemia].
Beris P; Rieder A; Andrey C; Helg C; Chapuis B
Schweiz Med Wochenschr; 1984 Dec; 114(48):1763-6. PubMed ID: 6596706
[TBL] [Abstract][Full Text] [Related]
13. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
Koyama S; Itou S; Shibata A
Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
[TBL] [Abstract][Full Text] [Related]
14. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
[TBL] [Abstract][Full Text] [Related]
15. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
[TBL] [Abstract][Full Text] [Related]
16. [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
Yoshida M; Tsunoda S; Akutsu M; Furukawa Y; Takeda K; Akashi M; Komatsu N; Muroi K; Ikeda K; Ohsaka A
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1057-62. PubMed ID: 3566302
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
18. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
19. [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
Lobato-Mendizábal E; Ruiz-Argüelles GJ; Marín-López A
Rev Invest Clin; 1989; 41(2):139-45. PubMed ID: 2675236
[TBL] [Abstract][Full Text] [Related]
20. [Low-dose oral etoposide and subcutaneous injection of low-dose cytosine arabinoside (Et-A non i.v.) with or without minimum anthracycline for refractory acute non-lymphoblastic leukemia].
Tsukaguchi M; Furukawa Y; Kitani T
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1603-7. PubMed ID: 9725056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
